157 related articles for article (PubMed ID: 12818444)
1. A pilot study of the use of low dose human menopausal gonadotropin in ovulation induction.
Ku SY; Suh CS; Kim SH; Choi YM; Kim JG; Moon SY
Eur J Obstet Gynecol Reprod Biol; 2003 Jul; 109(1):55-9. PubMed ID: 12818444
[TBL] [Abstract][Full Text] [Related]
2. [Effect of domestic highly purified urinary follicle stimulating hormone on outcomes of in vitro fertilization-embryo transfer in controlled ovarian stimulation].
Ye H; Huang GN; Cao YX; Zhong Y; Huang YH; Zhu GJ; Zhou LM; Chen ZJ; Shi JZ; Zeng Y; Weng N; Huang XF; Yang J; Zhu YM; Li YP; Yi D; Zhuang GL
Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):838-42. PubMed ID: 24444561
[TBL] [Abstract][Full Text] [Related]
3. A preliminary study on reduced dose (33 or 25 microg) gonadotropin-releasing hormone agonist long protocol for multifollicular ovarian stimulation in patients with high basal serum follicle-stimulating hormone levels undergoing in vitro fertilization-embryo transfer.
Ku SY; Choi YS; Jee BC; Suh CS; Choi YM; Kim JG; Moon SY; Kim SH
Gynecol Endocrinol; 2005 Oct; 21(4):227-31. PubMed ID: 16316845
[TBL] [Abstract][Full Text] [Related]
4. The effect of human menopausal gonadotrophin and highly purified, urine-derived follicle stimulating hormone on the outcome of in-vitro fertilization in down-regulated normogonadotrophic women.
Westergaard LG; Erb K; Laursen S; Rasmussen PE; Rex S
Hum Reprod; 1996 Jun; 11(6):1209-13. PubMed ID: 8671425
[TBL] [Abstract][Full Text] [Related]
5. Comparison of GnRH agonists and antagonists in unselected IVF/ICSI patients treated with different controlled ovarian hyperstimulation protocols: a matched study.
Del Gadillo JC; Siebzehnrübl E; Dittrich R; Wildt L; Lang N
Eur J Obstet Gynecol Reprod Biol; 2002 May; 102(2):179-83. PubMed ID: 11950487
[TBL] [Abstract][Full Text] [Related]
6. Supplementation with human menopausal gonadotropin in the gonadotropin-releasing hormone antagonist cycles of women with high AMH: Pregnancy outcomes and serial hormone levels.
Chen LH; Chin TH; Huang SY; Yu HT; Chang CL; Huang HY; Wang HS; Soong YK; Wu HM
Taiwan J Obstet Gynecol; 2021 Jul; 60(4):739-744. PubMed ID: 34247817
[TBL] [Abstract][Full Text] [Related]
7. Pure and highly purified follicle-stimulating hormone alone or in combination with human menopausal gonadotrophin for ovarian stimulation after pituitary suppression in in-vitro fertilization.
Balasch J; Fábregues F; Creus M; Moreno V; Puerto B; Peñarrubia J; Carmona F; Vanrell JA
Hum Reprod; 1996 Nov; 11(11):2400-4. PubMed ID: 8981119
[TBL] [Abstract][Full Text] [Related]
8. Inclusion of standard and low-dose gonadotropin releasing hormone-analog (short protocol) in controlled ovarian hyperstimulation regimens in normogonadotropic patients aged 40-48 years who are undergoing in vitro fertilization.
Avrech OM; Orvieto R; Pinkas H; Sapir-Rufas O; Feldberg D; Fisch B
Gynecol Endocrinol; 2004 Nov; 19(5):247-52. PubMed ID: 15726912
[TBL] [Abstract][Full Text] [Related]
9. [Comparison of GnRH antagonist fixed protocol and GnRH agonists long protocol in infertile patients with normal ovarian reserve function in their first in vitro fertilization-embryo transfer cycle].
Yang S; Chen XN; Qiao J; Liu P; Li R; Chen GA; Ma CH
Zhonghua Fu Chan Ke Za Zhi; 2012 Apr; 47(4):245-9. PubMed ID: 22781108
[TBL] [Abstract][Full Text] [Related]
10. The initial flare-up induced by gonadotropin releasing hormone agonist may serve as a predictor of ovarian response in the current IVF-ET treatment cycle in normogonadotropic women aged 40-48 years.
Avrech OM; Royburt M; Sabah G; Zukerman Z; Pinkas H; Amit S; Ovadia J; Fisch B
J Assist Reprod Genet; 1996 May; 13(5):395-400. PubMed ID: 8739055
[TBL] [Abstract][Full Text] [Related]
11. Can Ratios Between Prognostic Factors Predict the Clinical Pregnancy Rate in an IVF/ICSI Program with a GnRH Agonist-FSH/hMG Protocol? An Assessment of 2421 Embryo Transfers, and a Review of the Literature.
Merviel P; Menard M; Cabry R; Scheffler F; Lourdel E; Le Martelot MT; Roche S; Chabaud JJ; Copin H; Drapier H; Benkhalifa M; Beauvillard D
Reprod Sci; 2021 Feb; 28(2):495-509. PubMed ID: 32886340
[TBL] [Abstract][Full Text] [Related]
12. The effects of low-dose human chorionic gonadotropin combined with human menopausal gonadotropin protocol on women with hypogonadotropic hypogonadism undergoing ovarian stimulation for in vitro fertilization.
Jiang S; Kuang Y
Clin Endocrinol (Oxf); 2018 Jan; 88(1):77-87. PubMed ID: 28960429
[TBL] [Abstract][Full Text] [Related]
13. The impact of adding hp-hMG in r-FSH started GnRH antagonist cycles on ART outcome.
Kan O; Simsir C; Atabekoglu CS; Sonmezer M
Gynecol Endocrinol; 2019 Oct; 35(10):869-872. PubMed ID: 30973022
[TBL] [Abstract][Full Text] [Related]
14. Prediction of ovarian reserve based on day-3 serum follicle stimulating hormone concentrations during the pituitary suppression cycle using a gonadotropin releasing hormone agonist in patients undergoing in vitro fertilization-embryo transfer.
Onagawa T; Shibahara H; Ayustawati ; Machida S; Hirano Y; Hirashima C; Takamizawa S; Suzuki M
Gynecol Endocrinol; 2004 Jun; 18(6):335-40. PubMed ID: 15497496
[TBL] [Abstract][Full Text] [Related]
15. 450 IU versus 600 IU gonadotropin for controlled ovarian stimulation in poor responders: a randomized controlled trial.
Lefebvre J; Antaki R; Kadoch IJ; Dean NL; Sylvestre C; Bissonnette F; Benoit J; Ménard S; Lapensée L
Fertil Steril; 2015 Dec; 104(6):1419-25. PubMed ID: 26361207
[TBL] [Abstract][Full Text] [Related]
16. Clinical and endocrine effects of ovulation induction with FSH and hCG supplementation in low responders in the midfollicular phase. A pilot study.
Ferrari B; Barusi L; Coppola F
J Reprod Med; 2002 Feb; 47(2):137-43. PubMed ID: 11883353
[TBL] [Abstract][Full Text] [Related]
17. A prospective, randomized, controlled trial comparing highly purified hMG with recombinant FSH in women undergoing ICSI: ovarian response and clinical outcomes.
Kilani Z; Dakkak A; Ghunaim S; Cognigni GE; Tabarelli C; Parmegiani L; Filicori M
Hum Reprod; 2003 Jun; 18(6):1194-9. PubMed ID: 12773445
[TBL] [Abstract][Full Text] [Related]
18. Determination of the efficiency of controlled ovarian hyperstimulation in the gonadotropin-releasing hormone agonist-suppression cycle using the initial follicle count during gonadotropin stimulation.
Huang FJ; Chang SY; Tsai MY; Kung FT; Wu JF; Chang HW
J Assist Reprod Genet; 2001 Feb; 18(2):91-6. PubMed ID: 11285987
[TBL] [Abstract][Full Text] [Related]
19. A randomized comparison of two ovarian stimulation protocols with gonadotropin-releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recombinant follicle-stimulating hormone on cycle day 2 or 5 with the standard long GnRH agonist protocol.
Hohmann FP; Macklon NS; Fauser BC
J Clin Endocrinol Metab; 2003 Jan; 88(1):166-73. PubMed ID: 12519847
[TBL] [Abstract][Full Text] [Related]
20. [Correlation between serum inhibin B level after treatment with gonadotropin releasing hormone agonist and outcome of in vitro fertilization-embryo transfer].
Lin WQ; Yang HY; Lin JJ; Chen X; Ye BL
Zhonghua Fu Chan Ke Za Zhi; 2009 Apr; 44(4):260-2. PubMed ID: 19570462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
